Maze Therapeutics (NASDAQ:MAZE) CMO Sells $254,465.10 in Stock

Posted by Stanley Muller on Sep 8th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 9,705 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $26.22, for a total value of $254,465.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $134,965.89.
On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $135,155.82.
On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Performance

NASDAQ MAZE traded up $0.16 on Tuesday, hitting $26.37. 365,002 shares of the stock were exchanged, compared to its average volume of 636,081. The company has a market capitalization of $1.46 billion, a PE ratio of -10.46 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business’s fifty day moving average is $28.64 and its 200 day moving average is $30.92. Maze Therapeutics, Inc. has a 52 week low of $14.75 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on MAZE shares. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $66.00.

Get Our Latest Report on MAZE

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics during the 1st quarter worth $145,000. Rhumbline Advisers acquired a new position in Maze Therapeutics in the 1st quarter valued at $80,000. Geode Capital Management LLC lifted its position in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after acquiring an additional 18,773 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares during the period.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.